Sam G. Pappas
YOU?
Author Swipe
View article: Tetanus Toxoid Utilizes Dual-Faceted Anticancer Mechanism Through Targeting Tumoral Sialic Acids and Enhancing Cytotoxic CD4+ T cell Responses Against Pancreatic Cancer
Tetanus Toxoid Utilizes Dual-Faceted Anticancer Mechanism Through Targeting Tumoral Sialic Acids and Enhancing Cytotoxic CD4+ T cell Responses Against Pancreatic Cancer Open
Pancreatic ductal adenocarcinoma (PDAC) remains profoundly resistant to conventional chemotherapy and immunotherapeutic interventions. Innovative therapeutic modalities, particularly microbe-derived immunotherapies, have demonstrated durab…
View article: Liver regeneration after portal and hepatic vein embolization improves overall survival compared with portal vein embolization alone: mid-term survival analysis of the multicentre DRAGON 0 cohort
Liver regeneration after portal and hepatic vein embolization improves overall survival compared with portal vein embolization alone: mid-term survival analysis of the multicentre DRAGON 0 cohort Open
Background The purpose of this study was to compare 3-year overall survival after simultaneous portal (PVE) and hepatic vein (HVE) embolization versus PVE alone in patients undergoing liver resection for primary and secondary cancers of th…
View article: Utilization of Multiorgan Radiomics to Predict Future Liver Remnant Hypertrophy After Portal Vein Embolization: Another Tool for the Toolbox?
Utilization of Multiorgan Radiomics to Predict Future Liver Remnant Hypertrophy After Portal Vein Embolization: Another Tool for the Toolbox? Open
View article: Editorial: Different Methods of Minimally Invasive Esophagojejunostomy After Total Gastrectomy for Gastric Cancer: Outcomes from Two Experienced Centers
Editorial: Different Methods of Minimally Invasive Esophagojejunostomy After Total Gastrectomy for Gastric Cancer: Outcomes from Two Experienced Centers Open
View article: Sarcoidosis of the Bile Duct
Sarcoidosis of the Bile Duct Open
Sarcoidosis is an inflammatory disease that affects multiple organs. The lungs are the most commonly involved organs. Although a large proportion of patients with sarcoidosis have liver involvement, bile duct involvement is rare. Here, we …
View article: Correction: Refining colorectal cancer classification and clinical stratification through a single-cell atlas
Correction: Refining colorectal cancer classification and clinical stratification through a single-cell atlas Open
View article: Refining colorectal cancer classification and clinical stratification through a single-cell atlas
Refining colorectal cancer classification and clinical stratification through a single-cell atlas Open
View article: Additional file 7 of Refining colorectal cancer classification and clinical stratification through a single-cell atlas
Additional file 7 of Refining colorectal cancer classification and clinical stratification through a single-cell atlas Open
Additional file 7: Table S6. List of significant differentially expressed genes from Fibroblast.
View article: Additional file 3 of Refining colorectal cancer classification and clinical stratification through a single-cell atlas
Additional file 3 of Refining colorectal cancer classification and clinical stratification through a single-cell atlas Open
Additional file 3: Table S2. Cell count by cell type and patient from stromal, immune and Epithelial compartments.
View article: Additional file 8 of Refining colorectal cancer classification and clinical stratification through a single-cell atlas
Additional file 8 of Refining colorectal cancer classification and clinical stratification through a single-cell atlas Open
Additional file 8: Table S7. The P-values for pairwise t-tests comparisons (with Benjamani-Hochberg correction) of cell abundance across CMS.
View article: Additional file 6 of Refining colorectal cancer classification and clinical stratification through a single-cell atlas
Additional file 6 of Refining colorectal cancer classification and clinical stratification through a single-cell atlas Open
Additional file 6: Table S5. List of significant Pseudo Bulk differentially expressed genes in CMS from malignant cells.
View article: Additional file 12 of Refining colorectal cancer classification and clinical stratification through a single-cell atlas
Additional file 12 of Refining colorectal cancer classification and clinical stratification through a single-cell atlas Open
Additional file 12: Table S11. List of proportional hazard assumption ratio for survival from the samples in GSE17536 [45] and GSE39582 [48.
View article: Additional file 10 of Refining colorectal cancer classification and clinical stratification through a single-cell atlas
Additional file 10 of Refining colorectal cancer classification and clinical stratification through a single-cell atlas Open
Additional file 10: Table S9. List of significant differentially expressed genes from T-cells.
View article: Additional file 2 of Refining colorectal cancer classification and clinical stratification through a single-cell atlas
Additional file 2 of Refining colorectal cancer classification and clinical stratification through a single-cell atlas Open
Additional file 2: Table S1. Patient information, CMS classification and mutational status.
View article: Additional file 9 of Refining colorectal cancer classification and clinical stratification through a single-cell atlas
Additional file 9 of Refining colorectal cancer classification and clinical stratification through a single-cell atlas Open
Additional file 9: Table S8. List of significant differentially expressed genes from Myeloid cells.
View article: Additional file 4 of Refining colorectal cancer classification and clinical stratification through a single-cell atlas
Additional file 4 of Refining colorectal cancer classification and clinical stratification through a single-cell atlas Open
Additional file 4: Table S3. Cell counts by cell subtypes and samples from stromal and immune and epithelial compartments.
View article: Additional file 5 of Refining colorectal cancer classification and clinical stratification through a single-cell atlas
Additional file 5 of Refining colorectal cancer classification and clinical stratification through a single-cell atlas Open
Additional file 5: Table S4. Cell count by CMS subtype and patient from Epithelial compartments of Lee et al. 2020 [18] data and Our CRC data.
View article: Additional file 14 of Refining colorectal cancer classification and clinical stratification through a single-cell atlas
Additional file 14 of Refining colorectal cancer classification and clinical stratification through a single-cell atlas Open
Additional file 14: Table S13. Pathway analysis on the customized collection of 51 CRC-related gene sets.
View article: Additional file 13 of Refining colorectal cancer classification and clinical stratification through a single-cell atlas
Additional file 13 of Refining colorectal cancer classification and clinical stratification through a single-cell atlas Open
Additional file 13: Table S12. Multivariate-Cox regression analysis.
View article: Additional file 11 of Refining colorectal cancer classification and clinical stratification through a single-cell atlas
Additional file 11 of Refining colorectal cancer classification and clinical stratification through a single-cell atlas Open
Additional file 11: Table S10. Continuous subtype scoring across cell type (GSE39582 [45], GSE17536 [48]).
View article: Redefining colorectal cancer classification and clinical stratification through a single-cell atlas
Redefining colorectal cancer classification and clinical stratification through a single-cell atlas Open
Colorectal cancer (CRC), a disease of high incidence and mortality, has had few treatment advances owing to a large degree of inter- and intratumoral heterogeneity. Attempts to classify subtypes of colorectal cancer to develop treatment st…
View article: Preoperative portal vein or portal and hepatic vein embolization: DRAGON collaborative group analysis
Preoperative portal vein or portal and hepatic vein embolization: DRAGON collaborative group analysis Open
Background The extent of liver resection for tumours is limited by the expected functional reserve of the future liver remnant (FRL), so hypertrophy may be induced by portal vein embolization (PVE), taking 6 weeks or longer for growth. Thi…
View article: Current Status of Circulating Tumor DNA Liquid Biopsy in Pancreatic Cancer
Current Status of Circulating Tumor DNA Liquid Biopsy in Pancreatic Cancer Open
Pancreatic cancer is a challenging disease with a low 5-year survival rate. There are areas for improvement in the tools used for screening, diagnosis, prognosis, treatment selection, and assessing treatment response. Liquid biopsy, partic…
View article: Postoperative Chemotherapy for Thoracic Pathological T3N0M0 Esophageal Squamous Cell Carcinoma
Postoperative Chemotherapy for Thoracic Pathological T3N0M0 Esophageal Squamous Cell Carcinoma Open
View article: Matched whole-genome sequencing and whole-exome sequencing with circulating tumor DNA (ctDNA) analysis are complementary modalities in clinical practice
Matched whole-genome sequencing and whole-exome sequencing with circulating tumor DNA (ctDNA) analysis are complementary modalities in clinical practice Open
View article: Matched Whole-Genome Sequencing (WGS) and Whole-Exome Sequencing (WES) of Tumor Tissue with Circulating Tumor DNA (ctDNA) Analysis: Complementary Modalities in Clinical Practice
Matched Whole-Genome Sequencing (WGS) and Whole-Exome Sequencing (WES) of Tumor Tissue with Circulating Tumor DNA (ctDNA) Analysis: Complementary Modalities in Clinical Practice Open
Tumor heterogeneity, especially intratumoral heterogeneity, is a primary reason for treatment failure. A single biopsy may not reflect the complete genomic architecture of the tumor needed to make therapeutic decisions. Circulating tumor D…
View article: Evolving Clinical Utility of Liquid Biopsy in Gastrointestinal Cancers
Evolving Clinical Utility of Liquid Biopsy in Gastrointestinal Cancers Open
Room for improvement exists regarding recommendations for screening, staging, therapy selection, and frequency of surveillance of gastrointestinal cancers. Screening is costly and invasive, improved staging demands increased sensitivity an…
National Treatment Practice for Adrenocortical Carcinoma: Have They Changed and Have We Made Any Progress? Open
View article: Primary Tumor Site Affects Survival in Patients with Gastroenteropancreatic and Neuroendocrine Liver Metastases
Primary Tumor Site Affects Survival in Patients with Gastroenteropancreatic and Neuroendocrine Liver Metastases Open
Background . Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are commonly present with metastatic disease, and the liver is the most frequent metastatic site. Herein, we studied whether primary tumor site affects survival in patien…
View article: Comparison of Neoadjuvant Therapy Regimens and Tumor Regression Scoring Systems on Pancreatic Ductal Adenocarcinoma: An Institutional Experience
Comparison of Neoadjuvant Therapy Regimens and Tumor Regression Scoring Systems on Pancreatic Ductal Adenocarcinoma: An Institutional Experience Open
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of death in the United States. Most patients have locally advanced disease. Neoadjuvant therapy (NAT) was traditionally used only in unresectable cases. With the developme…